OBJECTIVE: To study the clinical effects of @entity2682 on the treatment of @entity111 resulting from deep partial-thickness burn. METHODS: A total of fifty-eight @entity1 suffering from @entity111 after deep partial-thickness burn were hospitalized from January 2013 to January 2014. @entity1 were divided into placebo group (n = 18, treated with oral @entity620 in the dose of 100 mg for 4 weeks, twice per day), @entity14746 group (n = 20, treated with oral @entity14746 in the dose of 10 mg for 4 weeks, twice per day), and @entity2682 group (n = 20, treated with oral @entity2682 in the dose of 300 mg for 4 weeks, twice per day). Before treatment and on @entity227 ( @entity227 ) 3 and 28, the Visual Analog Scale (VAS) was used to assess the itching degree, and the mean scores were recorded. The remission rates of @entity111 on @entity227 3 and 28 were calculated. The adverse effects were observed during treatment. Data were processed with analysis of variance, q test, and chi-square test. RESULTS: Compared with that before treatment, the itching degree of @entity1 with light, moderate, and severe itching in placebo group was not relieved after treatment; the itching degree of @entity1 with moderate or severe itching in @entity14746 group was alleviated after treatment, but not in @entity1 with light itching; itching degree of all @entity1 in @entity2682 group was significantly relieved after treatment. There were no obvious differences in VAS scores among the 3 groups before treatment (F = 2.78, P > 0.05). On @entity227 3 and 28, the VAS scores of @entity1 in both @entity2682 group [(2.3    0.8) and (0.6    0.3) points] and @entity14746 group [(4.2    1.7) and (2.8    1.2) points] were lower than those in placebo group [(5.7    2.0) and (5.7    1.9) points, with q values from 6.70 to 7.75, P values below 0.05]. The VAS scores of @entity1 in @entity2682 group on @entity227 3 and 28 were lower than those in @entity14746 group (with q values respectively 6.30 and 6.90, P values below 0.05). The remission rates of @entity111 of @entity1 in @entity2682 group on @entity227 3 and 28 were respectively (66    20)% and (91    17)%, and they were higher than those in @entity14746 group [(33    8)% and (56    14)%, with q values respectively 4.70 and 3.82, P values below 0.05]. The remission rate of @entity111 of @entity1 in placebo group on @entity227 3 and 28 was 0, which was lower than that of the other 2 groups each (with q values from 3.94 to 6.76, P values below 0.05). During the course of treatment, 5 @entity1 in @entity2682 group suffered from adverse effects including mild-to-moderate drowsiness and @entity1296 , but they disappeared one week later. No adverse effects were observed in @entity1 of the other two groups. CONCLUSIONS: For @entity1 with deep partial-thickness burn, @entity2682 can effectively alleviate @entity111 after wound healing with safety.

[Clinical effects of XXXX on the treatment of @entity111 resulting from deep partial-thickness burn].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity227 :: ('MESH:D014786', 'Disease') :: ['post treatment day', 'PTD'] @entity2682 :: ('MESH:C040029', 'Chemical') :: ['gabapentin'] @entity620 :: ('MESH:D001205', 'Chemical') :: ['vitamin C'] @entity111 :: ('MESH:D011537', 'Disease') :: ['scar itching', 'pruritus', 'pruritus of scar'] @entity14746 :: ('MESH:D017332', 'Chemical') :: ['cetirizine'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness']
@entity2682 :: (MESH:C040029,Chemical) :: ['gabapentin']
